Only qualified healthcare providers may order
Trusight Tumor 170 (TST170)
Every patient is unique, and so is their cancer. The constellation of mutations present in cancer cells plays a role in the patient’s response to therapy. Therefore, it is crucial to understand the pattern of mutations in order to select the most appropriate treatment for each person’s cancer. The TruSight Tumor 170 test is a next-generation sequencing assay designed to cover 170 genes associated with common solid tumors, including assessment of fusions, splice variants, insertions/deletions and single-nucleotide variants (SNVs), and amplifications. This comprehensive test helps providers diagnose and treat each unique cancer to improve patient outcomes.